Barrons:ResMed CEO Mick Farrell told Barron’s that the company had seen no impact on new patient flow because of GLP-1s. “We believe that increased utilization of GLP-1s to treat obesity will bring many new people into the healthcare funnel,” said Farrell in a written statement. “We believe that this will open them up to sleep apnea awareness, diagnosis, and treatment pathways.”
Many analysts think the drop in the sleep apnea stocks has more than accounted for the modest impact they foresee from GLP-1s. That was the thinking of Needham’s Mike Matson when he raised ResMed to a Buy this month.
Jefferies’ Will Sevush disagrees. Most sleep apnea patients are overweight, he told Barron’s, and studies of patients who had weight-loss surgery showed that many were relieved of their sleep apnea. “Obesity is clearly the driver,” said Sevush. “GLP-1s are going to impact everything that touches sleep apnea.”
Ann: ResMed Announces Results for the Fourth Quarter of FY2023, page-275
-
- There are more pages in this discussion • 97 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$35.64 |
Change
0.200(0.56%) |
Mkt cap ! $21.85B | |||
| Open | High | Low | Value | Volume |
| $35.60 | $35.82 | $35.51 | $35.56M | 997.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $35.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $35.70 | 15 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| RMD (ASX) Chart |